

1616



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

RECEIVED

JUN 21 2001

TECH CENTER 1600/2900

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

TELEPHONE: 512/474-5201
FACSIMILE: 512/536-4598

DAVID L. PARKER
PARTNER


INTERNET ADDRESS:
DPARKER@FULBRIGHT.COM

DIRECT DIAL: 512/536-3055

June 15, 2001

FILE: UTXC:528--1

10016657

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
6/15/01 Date	 Signature

Commissioner for Patents
Washington, DC 20231

RE: SN 09/415,890 "PARENTERAL PIMARICIN AS TREATMENT OF SYSTEMIC INFECTIONS" - Andersson, et al. (MDA96-033CON1)

Commissioner:


Enclosed for filing in the above-referenced patent application is:

- (1) An Amendment; and Response to Office Action dated March 15, 2001 including Appendices A and B; and
- (2) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10016657/01982.

Commissioner for Patents
June 15, 2001
Page 2

Respectfully submitted,

 REG. NO. 45,104

FOR David L. Parker
Reg. No. 32,165

DLP/jmh
Encl.: